TTM
−$3.41B
YoY change
-22.1%
5Y CAGR
—
Peak year (2021)
$13.30B
Cumulative operating income
$7.80B
Operating Income history chart for Moderna (MRNA) from 2016 to 2025
Latest: −$3.07B
Operating Income growth chart for Moderna (MRNA) from 2016 to 2025
Latest: -22.1%
Operating Income history table for Moderna (MRNA) from 2016 to 2025
| 2025 | −$3.07B | -22.1% | +$871.00M | ||
| 2024 | −$3.94B | -6.9% | +$294.00M | ||
| 2023 | −$4.24B | -145.0% | −$13.66B | ||
| 2022 | $9.42B | -29.2% | −$3.88B | ||
| 2021 | $13.30B | -1842.3% | +$14.06B | ||
| 2020 | −$763.14M | +39.8% | −$217.42M | ||
| 2019 | −$545.72M | +16.4% | −$76.85M | ||
| 2018 | −$468.87M | +74.1% | −$199.51M | ||
| 2017 | −$269.36M | +20.4% | −$45.59M | ||
| 2016 | −$223.77M | — | — |
- 2025−$3.07B-22.1%
- 2024−$3.94B-6.9%
- 2023−$4.24B-145.0%
- 2022$9.42B-29.2%
- 2021$13.30B-1842.3%
- 2020−$763.14M+39.8%
- 2019−$545.72M+16.4%
- 2018−$468.87M+74.1%
- 2017−$269.36M+20.4%
- 2016−$223.77M—
Operating Income values are taken from Moderna's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Operating Income at Moderna (MRNA)
According to Moderna's latest reported financial statements, the company's current operating income (TTM) is −$3.41B. Operating income is profit from core operations: revenue minus cost of goods sold and operating expenses (SG&A, R&D). It excludes interest, taxes, and non-operating items, so it isolates how profitable the business itself is before financing and tax decisions. Compare with EBITDA and net income.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
As of the 2025 fiscal year, Moderna (MRNA) reported operating income of −$3.07B – declined 22.1% year-over-year.
Between 2021 and 2025, Moderna operating income plunged 123.1%, falling from $13.30B to −$3.07B.
The record annual operating income stands at $13.30B, reached in 2021; the historical low of −$4.24B was recorded in 2023.
Moderna Operating Income by Year
Moderna Operating Income 2025: −$3.07B
Moderna operating income in 2025 was −$3.07B, declined 22.1% below 2024.
Moderna Operating Income 2024: −$3.94B
2024's operating income for Moderna came in at −$3.94B, declined 6.9% below 2023.
Moderna Operating Income 2023: −$4.24B
Moderna posted operating income of −$4.24B in 2023, plunged 145.0% below 2022. This figure represents the lowest annual value in the available history.
Moderna Operating Income 2022: $9.42B
In 2022, Moderna reported operating income of $9.42B, declined 29.2% below 2021.
Moderna Operating Income 2021: $13.30B
Moderna operating income in 2021 was $13.30B.
See more financial history for Moderna (MRNA).
Sector peers by Operating Income
Healthcare peers of Moderna (MRNA), ranked by their latest operating income
| $29.70B | |
| $25.60B | |
| $23.49B | |
| $20.09B | |
| $19.90B | |
| $18.96B | |
| $13.74B | |
| $10.68B |
- $29.70B
- $25.60B
- $23.49B
- $20.09B
- $19.90B
- $18.96B
- $13.74B
- $10.68B
Frequently asked questions
Moderna (MRNA) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation